615 Treatment comparison of patients with chronic hepatitis C and elevated ALT vs patients with persistently normal ALT — preliminary results of a prospective open trial

Vogel, W; Brünner, H; Rosenbeiger, M.; Graziadei, I.; Maieron, A; Jilek, Kurt; Stauber, R.E.; Wolkersdorfer, D.; Ulmer, Hanno

doi:10.1016/s0168-8278(06)80615-x

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of RVR, defined as undetectable HCV RNA or ≥2 log 10 drop at week 4 of treatment with pegylated interferon-α2a plus ribavirin 800 mg/ day, was 93% in genotype 2 or 3 patients with persistently normal ALT levels in a large randomized trial (the SVR rate was 75% in this subgroup) [37]. Preliminary results from another prospective study [38] showed that the incidence of undetectable HCV RNA was 93% at week 4 and 90% at week 12 among genotype 2 or 3 patients treated with pegylated interferon-α2b 1.5 µg/kg/week plus ribavirin 800-1,200 mg/ day. There was no difference between the number of patients with normal (n=24) or increased (n=30) ALT levels in this analysis [38].…”

Section: Is Abbreviated Therapy Suitable For All Patients?mentioning

confidence: 99%

“…Preliminary results from another prospective study [38] showed that the incidence of undetectable HCV RNA was 93% at week 4 and 90% at week 12 among genotype 2 or 3 patients treated with pegylated interferon-α2b 1.5 µg/kg/week plus ribavirin 800-1,200 mg/ day. There was no difference between the number of patients with normal (n=24) or increased (n=30) ALT levels in this analysis [38].…”

Section: Is Abbreviated Therapy Suitable For All Patients?mentioning

confidence: 99%

See 1 more Smart Citation

Management of Hepatitis C virus Genotype 2 or 3 Infection: Treatment Optimization on the Basis of Virological Response

et al. 2009

View full text Add to dashboard Cite

Current guidelines recommend a full 24-week regimen for all patients undergoing treatment for genotype 2 or 3 hepatitis C virus (HCV) infection. Recent data from two large randomized studies, one with pegylated interferon-α2a plus ribavirin (RBV) and one with pegylated interferon-α2b plus RBV assessed treatment duration and on-treatment predictors, such as rapid virological response (RVR; HCV RNA <50 IU/ml at week 4) or sustained virological response rates. Overall, these studies have shown that abbreviated regimens are generally less effective than standard 24-week regimens in genotype 2 or 3 patients because of a higher rate of relapse. However, abbreviated treatment might be offered to selected patients with an RVR provided that they have a low baseline viral load and minimal hepatic fibrosis.

show abstract

Section: Is Abbreviated Therapy Suitable For All Patients?mentioning

confidence: 99%

Section: Is Abbreviated Therapy Suitable For All Patients?mentioning

confidence: 99%